BioCentury
ARTICLE | Company News

Innovent gains INDO inhibitor from Chinese institute

September 8, 2017 11:05 PM UTC

The Shanghai Institute of Organic Chemistry at the Chinese Academy of Sciences granted Innovent Biologics Inc. (Suzhou, China) worldwide rights to a small molecule inhibitor of indoleamine 2,3-dioxygenase (INDO; IDO). Innovent plans to combine the INDO inhibitor with its PD-1 mAb IBI308.

The institute is to receive a total of $457 million in upfront and milestone payments, which Innovent said is the largest amount for an academic institution under a Chinese industry deal. The institute is also eligible for royalties...